Unlike general breast cancer which processes either receptors for estrogen or progesterone and/or receptors with a protein called HER2, triple-negative breast cancer is a form of breast cancer that does not share the aforementioned characteristics.
In other words, triple-negative breast cancer does not have receptors of estrogen or progesterone or genetic preposition.
More importantly, triple negative breast cancer was found to infect women under the age of 40 and women of African or Asian ancestry in the US, compared to breast cancer in the White.
Particularly, according to the epidemiological study, younger women and in women of African ancestry are susceptible to a higher risk of basal-like triple negative breast cancers.
Compared to the malignant nature, triple-negative and basal-like breast cancers are highly invasive which can grow and spread quickly to other tissues and organs through lymph and blood.
Also compared to other breast cancer, with decreased risk after 5 years, triple-negative breast cancers have a substantial higher recurrent rate within 5 years after treatment.
Triple negative breast cancer shares the symptoms similar to those of breast cancer and risk factor except in the form of the genetic preposition.
According to Dr. Shimelis H, the lead scientist in the joint study led by the Mayo Clinic, said, "Pathogenic variants in BRIP1, RAD51C, and TP53 were associated with moderate risk (odds ratio > 2) of TNBC. Similar trends were observed for the African American population. Pathogenic variants in these TNBC genes were detected in 12.0% (3.7% non-BRCA1/2) of all participants".
And, "Multigene hereditary cancer panel testing can identify women with an elevated risk of TNBC due to mutations in BARD1, BRCA1, BRCA2, PALB2, and RAD51D".
In other words, if you carry the mutated genes BARD1, BRCA1, BRCA2, PALB2, and RAD51D, you are at a higher risk of triple negative breast cancer.
In seeking a potential compound for the treatment of breast cancer, researchers reexamined the promising anticancer effects of novel C-substituted diindolylmethane (DIM) derivatives DIM-10 and DIM-14 in aggressive triple negative breast cancer (TNBC, MDA-MB-231) models.
In vitro studies, novel C-substituted diindolylmethane (DIM) derivatives DIM-10 and DIM-14 demonstrated strong anticancer effects.
NLC formulations. including DIM-10 and DIM-14 extended significant increase in oral bioavailability compared to poor permeability and poor oral bioavailability of DIM-10 and DIM-14 used alone in pharmacokinetic studies.
Futhermore, compared to DIM-10, DIM-10 used alone, the NLC formulation showed an increase in Cmax and AUC values by 4.73 and 11.19-folds.
Similar increased anti-aggressive triple negative breast cancer (TNBC) efficacy was also found in the DIM-14 NLC formulations.
In dogs, the DIM-10 NLC formulations showed an increase of 2.65 and 2.94-fold in Cmax and AUC, against triple negative breast cancer (TNBC) respectively.
Moreover, DIM-10 or DIM-14 NLC formulations demonstrated significant a reduction in tumor volumes TNBC models and treated animals.
Dr. Godugu C, the lead scientist after taking into account co and confounders wrote, "NLC formulation of both DIM-10 and 14 is effective in TNBC models".
Taken altogether, 3,3'-Diindolylmethane derived from the digestion of indole-3-carbinol may be considered a supplement for the prevention and treatment of triple negative breast cancer, pending to the confirmation of the larger sample size and multicenter human study.
Intake of 3,3'-diindolylmethane in form of supplement should be taken with extreme care to prevent overdose acute liver toxicity.
Natural Medicine for Fatty Liver And Obesity Reversal - The Revolutionary Findings To Achieve Optimal Health And Lose Weight
How To Get Rid Of Eye Floaters
Contrary To Professionals Prediction, Floaters Can Be Cured Naturally
Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months
Back to Kyle J. Norton Homepage http://kylejnorton.blogspot.ca
Author Biography
Kyle J. Norton (Scholar, Master of Nutrition, All right reserved)
Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, health blogs, self-growth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bioscience, ISSN 0975-6299.
Sources
(1) Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer by Godugu C1, Doddapaneni R2, Safe SH3, Singh M. (PubMed)
(2) Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing by Shimelis H1, LaDuca H2, Hu C1, Hart SN3, Na J3, Thomas A3, Akinhanmi M1, Moore RM3, Brauch H4,5,6, Cox A7, Eccles DM8, Ewart-Toland A9, Fasching PA10,11,12, Fostira F13, Garber J14, Godwin AK15, Konstantopoulou I13, Nevanlinna H16, Sharma P15, Yannoukakos D13, Yao S17, Feng BJ18, Tippin Davis B2, Lilyquist J3, Pesaran T2, Goldgar DE18, Polley EC3, Dolinsky JS2, Couch. (PubMed)
No comments:
Post a Comment